Trial Profile
AN OPEN-LABEL, SINGLE-ARM STUDY OF THE LONG-TERM SAFETY OF XALKORI (REGISTERED) IN PATIENTS FROM CHINA WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) OR ROS1 LOCUS WHO HAVE PREVIOUSLY BEEN TREATED ON A STUDY OF XALKORI (REGISTERED)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 17 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 30 Aug 2022 Planned End Date changed from 30 Dec 2026 to 30 Jun 2023.
- 30 Aug 2022 Planned primary completion date changed from 30 Dec 2026 to 30 Jun 2023.